Merck Manual

Please confirm that you are a health care professional

honeypot link

Cancer in Pregnancy


Lara A. Friel

, MD, PhD, University of Texas Health Medical School at Houston, McGovern Medical School

Reviewed/Revised Oct 2021 | Modified Sep 2022

Because embryonic tissues grow rapidly and have a high DNA turnover rate, they resemble cancer tissues and are thus very vulnerable to antineoplastic drugs. Many antimetabolites and alkylating drugs (eg, busulfan, chlorambucil, cyclophosphamide, 6-mercaptopurine, methotrexate) can cause fetal abnormalities. Methotrexate is particularly problematic; use during the 1st trimester increases risk of spontaneous abortion and, if the pregnancy continues, multiple congenital malformations. Although pregnancy often concludes successfully despite cancer treatment, risk of fetal injury due to treatment leads some women to choose abortion.

Rectal cancer

Rectal cancers Colorectal Cancer Colorectal cancer is extremely common. Symptoms include blood in the stool and change in bowel habits. Screening using one of several methods is recommended for appropriate populations. Diagnosis... read more Colorectal Cancer may require hysterectomy to ensure complete tumor removal. Cesarean delivery may be done as early as 28 weeks, followed by hysterectomy so that aggressive cancer treatment can be started.

Cervical cancer

Cervical cancer can develop during pregnancy, and an abnormal Papanicolaou (Pap) test should not be attributed to pregnancy. Abnormal Pap tests are followed by colposcopy and directed biopsies when indicated. Colposcopy does not increase risk of an adverse pregnancy outcome. Expert colposcopic evaluation and consultation with the pathologist are recommended before doing a cervical biopsy because the biopsy may cause hemorrhage and preterm labor. If the examination suggests that lesions are low-grade, a biopsy may not be done, particularly if cervical cytology also suggests that lesions are low-grade.

For carcinoma in situ (Federation of Gynecology and Obstetrics [FIGO] stage 0—see table FIGO Clinical Staging of Cervical Cancer Carcinoma FIGO Clinical Staging of Cervical Carcinoma* FIGO Clinical Staging of Cervical Carcinoma* ) and microinvasive cancer (stage IA1), treatment is often deferred until after delivery because at these stages, cancer progresses very slowly and pregnancy can be completed safely without affecting the woman's prognosis.

If invasive cancer (FIGO stage IA2 or higher) is diagnosed, pregnancy should be managed in consultation with a gynecologic oncologist. If invasive cancer is diagnosed during early pregnancy, immediate therapy appropriate for the cancer is traditionally recommended. If invasive cancer is diagnosed after 20 weeks and if the woman accepts the unquantified increase in risk, treatment can be deferred until into the 3rd trimester (eg, 32 weeks) to maximize fetal maturity but not delay treatment too long. For patients with invasive cancer, cesarean delivery with radical hysterectomy is done; vaginal delivery is avoided.

Other gynecologic cancers

Leukemia and Hodgkin lymphoma

Antineoplastic drugs typically used to treat lymphoma increase risk of fetal loss and congenital malformations.

Because leukemias can become fatal rapidly, treatment is given as soon as possible, without any significant delay to allow the fetus to mature.

If Hodgkin lymphoma is confined to above the diaphragm, radiation therapy may be used; the abdomen must be shielded. If lymphoma is below the diaphragm, abortion may be recommended.

Breast cancer

Drugs Mentioned In This Article

Drug Name Select Trade
Busulfex, Myleran
Cyclophosphamide, Cytoxan, Neosar
Purinethol, PURIXAN
Otrexup, Rasuvo, RediTrex, Rheumatrex, Trexall, Xatmep
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz!